In 2015, Fight Colorectal Cancer and the Cancer Research Institute announced their partnership designed to advance immunotherapy research for colorectal cancer, the third most common cancer diagnosed in U.S. men and women, and the second deadliest.

Recent studies have revealed that a subset of colorectal cancer patients with high levels of mutations in their tumors is more likely to respond to treatment with a type of immunotherapy called checkpoint blockade. Through our partnership with Fight CRC, we convened a working group of experts to discuss and publish results on the potential for breakthrough immunotherapies to treat more CRC patients successfully. The two organizations are also co-funding research grants to carry forward the working group’s findings.

*Immunotherapy results may vary from patient to patient.